Carcinoma of Unknown Primary Clinical Trial
Official title:
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00003943 -
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
|
Phase 2 | |
Completed |
NCT00002507 -
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Recruiting |
NCT03740503 -
Genomic Investigation of Unusual Responders
|
||
Terminated |
NCT00148135 -
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
|
Phase 2 | |
Completed |
NCT00003582 -
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00014456 -
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
Completed |
NCT00357630 -
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
|
Phase 2 | |
Active, not recruiting |
NCT01366144 -
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Completed |
NCT00004922 -
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00119314 -
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00047125 -
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
|
Phase 3 | |
Completed |
NCT00003657 -
High-dose ICE With Amifostine
|
Phase 2 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Recruiting |
NCT02764216 -
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
|
Phase 2 | |
Completed |
NCT00873119 -
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
|
Phase 2 | |
Completed |
NCT00388024 -
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
|
N/A | |
Completed |
NCT00066781 -
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
|
Phase 2 |